All In Biotech

Drug Trial Radar · NCT06527365

Safety and Efficacy of VDPHL01 in Males and Females With AGA

An Open-Label Multi-Dose Study to Evaluate the Safety and Efficacy of VDPHL01 in Male and Female Subjects With Androgenetic Alopecia

Last checked: Nov 19, 2026Latest source record: Nov 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

70

Planned (sponsor's estimate)

Start

Jul 8, 2024

Primary completion

Aug 2026

Study completion Aug 2026

Sponsor

Lead sponsor
Veradermics, Inc.Industry
Sponsor type
Industry
First posted
Jul 30, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of VDPHL01 in male and female subjects with Androgenetic Alopecia (AGA). AGA (or pattern of hair loss) is a genetic disorder caused by an excessive (too much) hair follicle response to androgens (hormone) that causes hair loss. VDPHL01 8.5 mg Tablets for males and VDPHL01 4.5 mg Tablets for females are an investigational oral drug to treat male and female pattern baldness. This multiple center, open-label, study will last about 13 months and includes 11 study visits (screening, baseline (day 1), week 2, month 1, month 2, month 4, month 6, month 8, month 10, month 12, month 13). Male subjects that meet the study eligibility criteria will be administered VDPHL01 once daily for 12 months. Female subjects that meet the study eligibility criteria will be administered VDPHL01 either once or twice daily for 12 months.

Conditions

  • Androgenetic Alopecia
  • AGA
  • Male Pattern Baldness

Interventions

  • VDPHL01Drug

    VDPHL01 Extended Release (ER) Tablet

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Changes in non-vellus Total Area Hair Count (TAHC)Time frame: Month 12
  2. Subjects Evaluation of Treatment BenefitTime frame: Month 12

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • 01

    San Diego, California

  • 04

    New Albany, Indiana

  • 03

    Hackensack, New Jersey

  • 02

    South Jordan, Utah

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.